{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T14:20:38Z","timestamp":1784557238245,"version":"3.55.0"},"reference-count":43,"publisher":"Bioscientifica","issue":"12","content-domain":{"domain":["erc.bioscientifica.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2023,9,29]]},"abstract":"<jats:p>\n                    Ataxia telangiectasia and Rad3-related protein (ATR) is a critical component of the DNA damage response and a potential target in the treatment of cancers. An ATR inhibitor, BAY 1895344, was evaluated for its use in differentiated thyroid cancer (DTC) therapy. BAY 1895344 inhibited cell viability in four DTC cell lines (TPC1, K1, FTC-133, and FTC-238) in a dose-dependent manner. BAY 1895344 treatment arrested DTC cells in the G2\/M phase, increased caspase-3 activity, and caused apoptosis. BAY 1895344 in combination with either sorafenib or lenvatinib showed mainly synergistic effects in four DTC cell lines. The combination of BAY 1895344 with dabrafenib plus trametinib revealed synergistic effects in K1 cells that harbor\n                    <jats:italic>BRAF<\/jats:italic>\n                    V600E. BAY 1895344 monotherapy retarded the growth of K1 and FTC-133 tumors in xenograft models. The combinations of BAY 1895344 plus lenvatinib and BAY 1895344 with dabrafenib plus trametinib were more effective than any single therapy in a K1 xenograft model. No appreciable toxicity appeared in animals treated with either a single therapy or a combination treatment. Our findings provide the rationale for the development of clinical trials of BAY 1895344 in the treatment of DTC.\n                  <\/jats:p>","DOI":"10.1530\/erc-23-0142","type":"journal-article","created":{"date-parts":[[2023,9,30]],"date-time":"2023-09-30T05:51:19Z","timestamp":1696053079000},"update-policy":"https:\/\/doi.org\/10.1530\/crossmarkpolicy-8","source":"Crossref","is-referenced-by-count":6,"title":["Therapeutic inhibition of ATR in differentiated thyroid cancer"],"prefix":"10.1530","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8877-9685","authenticated-orcid":true,"given":"Shu-Fu","family":"Lin","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan"},{"name":"College of Medicine, Chang Gung University, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Yin","family":"Lee","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ming-Hsien","family":"Wu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, New Taipei Municipal TuCheng Hospital, New Taipei City, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Ling","family":"Lu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Chang Gung Memorial Hospital, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chun-Nan","family":"Yeh","sequence":"additional","affiliation":[{"name":"Department of Surgery, Chang Gung Memorial Hospital, Taoyuan, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei-Yi","family":"Chen","sequence":"additional","affiliation":[{"name":"Institute of Biochemistry and Molecular Biology, National Yang Ming Chiao Tung University, Taipei, Taiwan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Chao","family":"Chou","sequence":"additional","affiliation":[{"name":"Laboratory of Preclinical Pharmacology Core, Memorial Sloan Kettering Cancer Center, New York, New York, USA"},{"name":"PD Science, Inc., Mill Run, Paramus, New Jersey, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J","family":"Wong","sequence":"additional","affiliation":[{"name":"Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"416","reference":[{"key":"bib1","series-title":"Cancers","first-page":"2104","article-title":"Novel targeted therapies for metastatic thyroid cancer-a comprehensive review","volume":"12","author":"Al-Jundi","year":"2020","unstructured":"Al-Jundi MThakur SGubbi S & Klubo-Gwiezdzinska J2020Novel targeted therapies for metastatic thyroid cancer-a comprehensive review. Cancers122104. (https:\/\/doi.org\/10.3390\/cancers12082104)"},{"key":"bib2","series-title":"Nature Reviews. Clinical Oncology","first-page":"564","article-title":"Synthetic lethal therapies for cancer: what's next after PARP inhibitors?","volume":"15","author":"Ashworth","year":"2018","unstructured":"Ashworth A & Lord CJ2018Synthetic lethal therapies for cancer: what's next after PARP inhibitors?Nature Reviews. Clinical Oncology15564\u2013576. (https:\/\/doi.org\/10.1038\/s41571-018-0055-6)"},{"key":"bib3","series-title":"Current Research in Pharmacology and Drug Discovery","first-page":"100017","article-title":"Progress towards a clinically-successful ATR inhibitor for cancer therapy","volume":"2","author":"Barnieh","year":"2021","unstructured":"Barnieh FMLoadman PM & Falconer RA2021Progress towards a clinically-successful ATR inhibitor for cancer therapy. Current Research in Pharmacology and Drug Discovery2100017. (https:\/\/doi.org\/10.1016\/j.crphar.2021.100017)"},{"key":"bib4","series-title":"Lancet","first-page":"319","article-title":"Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial","volume":"384","author":"Brose","year":"2014","unstructured":"Brose MSNutting CMJarzab BElisei RSiena SBastholt Lde la Fouchardiere CPacini FPaschke RShong YK, 2014Sorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trial. Lancet384319\u2013328. (https:\/\/doi.org\/10.1016\/S0140-6736(1460421-9)"},{"key":"bib5","series-title":"Lancet. Oncology","first-page":"1126","article-title":"Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"22","author":"Brose","year":"2021","unstructured":"Brose MSRobinson BSherman SIKrajewska JLin CCVaisman FHoff AOHitre EBowles DWHernando J, 2021Cabozantinib for radioiodine-refractory differentiated thyroid cancer (COSMIC-311): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. Oncology221126\u20131138. (https:\/\/doi.org\/10.1016\/S1470-2045(2100332-6)"},{"key":"bib6","series-title":"Cancer Discovery","first-page":"20","article-title":"Targeting DNA repair in cancer: beyond PARP inhibitors","volume":"7","author":"Brown","year":"2017","unstructured":"Brown JSO'Carrigan BJackson SP & Yap TA2017Targeting DNA repair in cancer: beyond PARP inhibitors. Cancer Discovery720\u201337. (https:\/\/doi.org\/10.1158\/2159-8290.CD-16-0860)"},{"key":"bib7","series-title":"Nature Reviews. Clinical Oncology","first-page":"395","article-title":"Targeting apoptosis in cancer therapy","volume":"17","author":"Carneiro","year":"2020","unstructured":"Carneiro BA & El-Deiry WS2020Targeting apoptosis in cancer therapy. Nature Reviews. Clinical Oncology17395\u2013417. (https:\/\/doi.org\/10.1038\/s41571-020-0341-y)"},{"key":"bib8","series-title":"CompuSyn for Drug Combinations and for General Dose-Effect Analysis","author":"Chou","year":"2005","unstructured":"Chou TC & Martin N2005CompuSyn for Drug Combinations and for General Dose-Effect Analysis. CompuSyn for Drug Combinations: PC Software and Users Guide: A Computer Program for Quantitation of Synergism and Antagonism in Drug Combinations and the Determination of IC50, ED50, and LD50 Values, Paramus, NJ, USA: ComboSyn Inc."},{"key":"bib9","series-title":"Pharmacological Reviews","first-page":"621","article-title":"Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies","volume":"58","author":"Chou","year":"2006","unstructured":"Chou TC2006Theoretical basis, experimental design, and computerized simulation of synergism and antagonism in drug combination studies. Pharmacological Reviews58621\u2013681. (https:\/\/doi.org\/10.1124\/pr.58.3.10)"},{"key":"bib10","series-title":"Nature Reviews. Molecular Cell Biology","first-page":"616","article-title":"ATR: an essential regulator of genome integrity","volume":"9","author":"Cimprich","year":"2008","unstructured":"Cimprich KA & Cortez D2008ATR: an essential regulator of genome integrity. Nature Reviews. Molecular Cell Biology9616\u2013627. (https:\/\/doi.org\/10.1038\/nrm2450)"},{"key":"bib11","series-title":"Surgery","first-page":"1195","article-title":"Defective thyrotropin receptor G-protein cyclic adenosine monophosphate signaling mechanism in the FTC human follicular thyroid cancer cell line","volume":"122","author":"Demeure","year":"1997","unstructured":"Demeure MJDoffek KM & Wilson SD1997Defective thyrotropin receptor G-protein cyclic adenosine monophosphate signaling mechanism in the FTC human follicular thyroid cancer cell line. Surgery1221195\u2013201; discussion 1201. (https:\/\/doi.org\/10.1016\/S0039-6060(9790227-0)"},{"key":"bib12","series-title":"Nature Communications","first-page":"4297","article-title":"Therapeutic targeting of ATR in alveolar rhabdomyosarcoma","volume":"13","author":"Dorado Garcia","year":"2022","unstructured":"Dorado Garcia HPusch FBei Yvon Stebut JIbanez GGuillan KImami KGurgen DRolff JHelmsauer K, 2022Therapeutic targeting of ATR in alveolar rhabdomyosarcoma. Nature Communications134297. (https:\/\/doi.org\/10.1038\/s41467-022-32023-7)"},{"key":"bib13","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"2892","article-title":"Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy","volume":"91","author":"Durante","year":"2006","unstructured":"Durante CHaddy NBaudin ELeboulleux SHartl DTravagli JPCaillou BRicard MLumbroso JDDe Vathaire F, 2006Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. Journal of Clinical Endocrinology and Metabolism912892\u20132899. (https:\/\/doi.org\/10.1210\/jc.2005-2838)"},{"key":"bib14","series-title":"Pharmacology and Therapeutics","first-page":"155","article-title":"Targeting the replication stress response in cancer","volume":"188","author":"Forment","year":"2018","unstructured":"Forment JV & O'Connor MJ2018Targeting the replication stress response in cancer. Pharmacology and Therapeutics188155\u2013167. (https:\/\/doi.org\/10.1016\/j.pharmthera.2018.03.005)"},{"key":"bib15","series-title":"European Thyroid Journal","first-page":"227","article-title":"2019 European Thyroid Association Guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer","volume":"8","author":"Fugazzola","year":"2019","unstructured":"Fugazzola LElisei RFuhrer DJarzab BLeboulleux SNewbold K & Smit J20192019 European Thyroid Association Guidelines for the treatment and follow-up of advanced radioiodine-refractory thyroid cancer. European Thyroid Journal8227\u2013245. (https:\/\/doi.org\/10.1159\/000502229)"},{"key":"bib16","series-title":"Nature Reviews. Cancer","first-page":"78","article-title":"Targeting DNA damage response pathways in cancer","volume":"23","author":"Groelly","year":"2023","unstructured":"Groelly FJFawkes MDagg RABlackford AN & Tarsounas M2023Targeting DNA damage response pathways in cancer. Nature Reviews. Cancer2378\u201394. (https:\/\/doi.org\/10.1038\/s41568-022-00535-5)"},{"key":"bib17","series-title":"Cell","first-page":"646","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","unstructured":"Hanahan D & Weinberg RA2011Hallmarks of cancer: the next generation. Cell144646\u2013674. (https:\/\/doi.org\/10.1016\/j.cell.2011.02.013)"},{"key":"bib18","series-title":"Thyroid","first-page":"1","article-title":"2015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer","volume":"26","author":"Haugen","year":"2016","unstructured":"Haugen BRAlexander EKBible KCDoherty GMMandel SJNikiforov YEPacini FRandolph GWSawka AMSchlumberger M, 20162015 American Thyroid Association management guidelines for adult patients with thyroid nodules and differentiated thyroid cancer: the American Thyroid Association guidelines task force on thyroid nodules and differentiated thyroid cancer. Thyroid261\u2013133. (https:\/\/doi.org\/10.1089\/thy.2015.0020)"},{"key":"bib19","series-title":"Carcinogenesis","first-page":"687","article-title":"Sensing and repairing DNA double-strand breaks","volume":"23","author":"Jackson","year":"2002","unstructured":"Jackson SP2002Sensing and repairing DNA double-strand breaks. Carcinogenesis23687\u2013696. (https:\/\/doi.org\/10.1093\/carcin\/23.5.687)"},{"key":"bib20","series-title":"Annals of Surgery","first-page":"466","article-title":"The prevalence and prognostic value of BRAF mutation in thyroid cancer","volume":"246","author":"Kebebew","year":"2007","unstructured":"Kebebew EWeng JBauer JRanvier GClark OHDuh QYShibru DBastian B & Griffin A2007The prevalence and prognostic value of BRAF mutation in thyroid cancer. Annals of Surgery246466\u2013471. (https:\/\/doi.org\/10.1097\/SLA.0b013e318148563d)"},{"key":"bib21","series-title":"Clinical Cancer Research","first-page":"3097","article-title":"Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant models","volume":"23","author":"Kim","year":"2017","unstructured":"Kim HGeorge ERagland RRafail SZhang RKrepler CMorgan MHerlyn MBrown E & Simpkins F2017Targeting the ATR\/CHK1 axis with PARP inhibition results in tumor regression in BRCA-mutant models. Clinical Cancer Research233097\u20133108. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-16-2273)"},{"key":"bib22","series-title":"Blood","first-page":"582","article-title":"ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells","volume":"127","author":"Kwok","year":"2016","unstructured":"Kwok MDavies NAgathanggelou ASmith EOldreive CPetermann EStewart GBrown JLau APratt G, 2016ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells. Blood127582\u2013595. (https:\/\/doi.org\/10.1182\/blood-2015-05-644872)"},{"key":"bib23","series-title":"Endocrine-Related Cancer","first-page":"727","article-title":"Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer","volume":"26","author":"Lin","year":"2019","unstructured":"Lin SFLin JDYeh CNHuang YTChou TC & Wong RJ2019Targeting PLKs as a therapeutic approach to well-differentiated thyroid cancer. Endocrine-Related Cancer26727\u2013738. (https:\/\/doi.org\/10.1530\/ERC-18-0555)"},{"key":"bib24","series-title":"Journal of the Formosan Medical Association","first-page":"189","article-title":"Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan","volume":"120","author":"Lin","year":"2021","unstructured":"Lin CYChang JSHuang SMHung CJHung CLChang CTYang HRHsieh TCHuang YH & Tsai HJ2021Experience of sorafenib treatment in differentiated thyroid cancer from Taiwan. Journal of the Formosan Medical Association120189\u2013195. (https:\/\/doi.org\/10.1016\/j.jfma.2020.04.021)"},{"key":"bib25","series-title":"Nature Communications","first-page":"579","article-title":"Regulation of mutant tert by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer","volume":"9","author":"Liu","year":"2018","unstructured":"Liu RYZhang TZhu GW & Xing MZ2018Regulation of mutant tert by BRAF V600E\/MAP kinase pathway through FOS\/GABP in human cancer. Nature Communications9579. (https:\/\/doi.org\/10.1038\/s41467-018-03033-1)"},{"key":"bib26","series-title":"Oncogene","first-page":"4869","article-title":"Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells","volume":"39","author":"Lloyd","year":"2020","unstructured":"Lloyd RLWijnhoven PWGRamos-Montoya AWilson ZIlluzzi GFalenta KJones GNJames NChabbert CDStott J, 2020Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells. Oncogene394869\u20134883. (https:\/\/doi.org\/10.1038\/s41388-020-1328-y)"},{"key":"bib27","series-title":"Cancers","first-page":"3487","article-title":"Efficacy and biomarker analysis of adavosertib in differentiated thyroid cancer","volume":"13","author":"Lu","year":"2021","unstructured":"Lu YLWu MHLee YYChou TCWong RJ & Lin SF2021Efficacy and biomarker analysis of adavosertib in differentiated thyroid cancer. Cancers133487. (https:\/\/doi.org\/10.3390\/cancers13143487)"},{"key":"bib28","series-title":"Journal of Hematology and Oncology","first-page":"43","article-title":"Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand","volume":"12","author":"Mei","year":"2019","unstructured":"Mei LZhang JHe K & Zhang J2019Ataxia telangiectasia and Rad3-related inhibitors and cancer therapy: where we stand. Journal of Hematology and Oncology1243. (https:\/\/doi.org\/10.1186\/s13045-019-0733-6)"},{"key":"bib30","series-title":"Oncotarget","first-page":"32396","article-title":"Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition","volume":"6","author":"Middleton","year":"2015","unstructured":"Middleton FKPatterson MJElstob CJFordham SHerriott AWade MAMcCormick AEdmondson RMay FEAllan JM, 2015Common cancer-associated imbalances in the DNA damage response confer sensitivity to single agent ATR inhibition. Oncotarget632396\u201332409. (https:\/\/doi.org\/10.18632\/oncotarget.6136)"},{"key":"bib33","series-title":"Nature Reviews. Clinical Oncology","first-page":"81","article-title":"State-of-the-art strategies for targeting the DNA damage response in cancer","volume":"16","author":"Pili\u00e9","year":"2019","unstructured":"Pili\u00e9 PGTang CMills GB & Yap TA2019State-of-the-art strategies for targeting the DNA damage response in cancer. Nature Reviews. Clinical Oncology1681\u2013104. (https:\/\/doi.org\/10.1038\/s41571-018-0114-z)"},{"key":"bib34","series-title":"Nature Chemical Biology","first-page":"428","article-title":"Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR","volume":"7","author":"Reaper","year":"2011","unstructured":"Reaper PMGriffiths MRLong JMCharrier JDMacCormick SCharlton PAGolec JMC & Pollard JR2011Selective killing of ATM- or p53-deficient cancer cells through inhibition of ATR. Nature Chemical Biology7428\u2013430. (https:\/\/doi.org\/10.1038\/Nchembio.573)"},{"key":"bib35","series-title":"Nature Cancer","first-page":"312","article-title":"Combined inhibition of aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma","volume":"2","author":"Roeschert","year":"2021","unstructured":"Roeschert IPoon EHenssen AGGarcia HDGatti MGiansanti CJamin YAde CPGallant PSchulein-Volk C, 2021Combined inhibition of aurora-A and ATR kinase results in regression of MYCN-amplified neuroblastoma. Nature Cancer2312\u2013326. (https:\/\/doi.org\/10.1038\/s43018-020-00171-8)"},{"key":"bib36","series-title":"Nature Reviews. Cancer","first-page":"20","article-title":"DNA damage and the balance between survival and death in cancer biology","volume":"16","author":"Roos","year":"2016","unstructured":"Roos WPThomas AD & Kaina B2016DNA damage and the balance between survival and death in cancer biology. Nature Reviews. Cancer1620\u201333. (https:\/\/doi.org\/10.1038\/nrc.2015.2)"},{"key":"bib37","series-title":"New England Journal of Medicine","first-page":"621","article-title":"Lenvatinib versus placebo in radioiodine-refractory thyroid cancer","volume":"372","author":"Schlumberger","year":"2015","unstructured":"Schlumberger MTahara MWirth LJRobinson BBrose MSElisei RHabra MANewbold KShah MHHoff AO, 2015Lenvatinib versus placebo in radioiodine-refractory thyroid cancer. New England Journal of Medicine372621\u2013630. (https:\/\/doi.org\/10.1056\/NEJMoa1406470)"},{"key":"bib38","series-title":"Nature Reviews. Endocrinology","first-page":"176","article-title":"Current practice in patients with differentiated thyroid cancer","volume":"17","author":"Schlumberger","year":"2021","unstructured":"Schlumberger M & Leboulleux S2021Current practice in patients with differentiated thyroid cancer. Nature Reviews. Endocrinology17176\u2013188. (https:\/\/doi.org\/10.1038\/s41574-020-00448-z)"},{"key":"bib39","series-title":"Journal of Clinical Endocrinology and Metabolism","first-page":"4331","article-title":"Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification","volume":"93","author":"Schweppe","year":"2008","unstructured":"Schweppe REKlopper JPKorch CPugazhenthi UBenezra MKnauf JAFagin JAMarlow LACopland JASmallridge RC, 2008Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification. Journal of Clinical Endocrinology and Metabolism934331\u20134341. (https:\/\/doi.org\/10.1210\/jc.2008-1102)"},{"key":"bib40","series-title":"Nature Communications","first-page":"6813","article-title":"ATR inhibition enables complete tumour regression in ALK-driven NB mouse models","volume":"12","author":"Szydzik","year":"2021","unstructured":"Szydzik JLind DEArefin BKurhe YUmapathy GSiaw JTClaeys AGabre JLVan den Eynden JHallberg B, 2021ATR inhibition enables complete tumour regression in ALK-driven NB mouse models. Nature Communications126813. (https:\/\/doi.org\/10.1038\/s41467-021-27057-2)"},{"key":"bib42","series-title":"Molecular Cancer Therapeutics","first-page":"26","article-title":"The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models","volume":"19","author":"Wengner","year":"2020","unstructured":"Wengner AMSiemeister GLucking ULefranc JWortmann LLienau PBader BBomer UMoosmayer DEberspacher U, 2020The novel ATR inhibitor BAY 1895344 is efficacious as monotherapy and combined with DNA damage-inducing or repair-compromising therapies in preclinical cancer models. Molecular Cancer Therapeutics1926\u201338. (https:\/\/doi.org\/10.1158\/1535-7163.MCT-19-0019)"},{"key":"bib43","series-title":"JAMA","first-page":"1493","article-title":"Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer","volume":"309","author":"Xing","year":"2013","unstructured":"Xing MZAlzahrani ASCarson KAViola DElisei RBendlova BYip LMian CVianello FTuttle RM, 2013Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer. JAMA3091493\u20131501. (https:\/\/doi.org\/10.1001\/jama.2013.3190)"},{"key":"bib44","series-title":"Clinical Cancer Research","first-page":"5213","article-title":"Ceralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study","volume":"27","author":"Yap","year":"2021a","unstructured":"Yap TAKrebs MGPostel-Vinay SEl-Khouiery ASoria JCLopez JBerges ACheung SYAIrurzun-Arana IGoldwin A, 2021aCeralasertib (AZD6738), an oral ATR kinase inhibitor, in combination with carboplatin in patients with advanced solid tumors: a phase I study. Clinical Cancer Research275213\u20135224. (https:\/\/doi.org\/10.1158\/1078-0432.CCR-21-1032)"},{"key":"bib45","series-title":"Cancer Discovery","first-page":"80","article-title":"First-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors","volume":"11","author":"Yap","year":"2021b","unstructured":"Yap TATan DSPTerbuch ACaldwell RGuo CGoh BCHeong VHaris NRMBashir SDrew Y, 2021bFirst-in-human trial of the oral ataxia telangiectasia and Rad3-related (ATR) inhibitor BAY 1895344 in patients (pts) with advanced solid tumors. Cancer Discovery1180\u201391. (https:\/\/doi.org\/10.1158\/2159-8290.CD-20-0868)"},{"key":"bib46","series-title":"Annual Review of Genetics","first-page":"155","article-title":"Functions, regulation, and therapeutic implications of the ATR checkpoint pathway","volume":"50","author":"Yazinski","year":"2016","unstructured":"Yazinski SA & Zou L2016Functions, regulation, and therapeutic implications of the ATR checkpoint pathway. Annual Review of Genetics50155\u2013173. (https:\/\/doi.org\/10.1146\/annurev-genet-121415-121658)"},{"key":"bib47","series-title":"Endocrine Connections","first-page":"754","article-title":"Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy","volume":"8","author":"Zhu","year":"2019","unstructured":"Zhu GDeng YPan LOuyang WFeng HWu JChen PWang JChen Y & Luo J2019Clinical significance of the BRAFV600E mutation in PTC and its effect on radioiodine therapy. Endocrine Connections8754\u2013763. (https:\/\/doi.org\/10.1530\/EC-19-0045)"}],"container-title":["Endocrine-Related Cancer"],"original-title":[],"link":[{"URL":"https:\/\/erc.bioscientifica.com\/view\/journals\/erc\/30\/12\/ERC-23-0142.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/30\/12\/ERC-23-0142.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/erc.bioscientifica.com\/downloadpdf\/journals\/erc\/30\/12\/ERC-23-0142.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T13:56:38Z","timestamp":1784555798000},"score":1,"resource":{"primary":{"URL":"http:\/\/journals.bioscientifica.com\/erc\/article\/25753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,9,29]]},"references-count":43,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.1530\/erc-23-0142","relation":{},"ISSN":["1351-0088","1479-6821"],"issn-type":[{"value":"1351-0088","type":"print"},{"value":"1479-6821","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,9,29]]}}}